A carregar...
Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL
Deep remission and prolonged disease-free survival can be achieved with first-line chemoimmunotherapy (CIT), such as combined fludarabine, cyclophosphamide, and rituximab, in the majority of patients with chronic lymphocytic leukemia (CLL). More modest results are reported with less intense regimens...
Na minha lista:
| Publicado no: | Blood |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4828075/ https://ncbi.nlm.nih.gov/pubmed/26576865 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-08-634816 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|